Apollo Hospitals shares hit a record high as HSBC upgrades to 'buy' with a higher PT, citing the demerger of the pharmacy business for value unlock.

• HSBC raises price target to 8,435 rupees, 12.5% upside, citing pharmacy demerger to simplify structure and boost valuation.
• 25 analysts average 'buy' rating, median PT at 8,288 rupees, as shares outperform Nifty 50 with 2% YTD gain.
• Demerger is expected to unlock pharmacy value, streamline operations, and attract execution, leading to investor confidence.